Concert Pharmaceuticals Inc. (CNCE): Odds are Looking Good after Recent Activity – Invest Chronicle

Concert Pharmaceuticals Inc. (CNCE): Odds are Looking Good after Recent Activity

Let’s start up with the current stock price of Concert Pharmaceuticals Inc. (CNCE), which is $3.45 to be very precise. The Stock rose vividly during the last session to $3.50 after opening rate of $3.15 while the lowest price it went was recorded $3.10 before closing at $2.81.Recently in News on May 5, 2022, Concert Pharmaceuticals Reports First Quarter 2022 Financial Results. Phase 3 Data Readout in Alopecia Areata Expected Second Quarter of 2022. You can read further details here

Concert Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.05 on 03/24/22, with the lowest value was $2.57 for the same time period, recorded on 02/24/22.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Concert Pharmaceuticals Inc. (CNCE) full year performance was -11.31%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Concert Pharmaceuticals Inc. shares are logging -25.32% during the 52-week period from high price, and 34.24% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.57 and $4.62.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 728046 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Concert Pharmaceuticals Inc. (CNCE) recorded performance in the market was 9.52%, having the revenues showcasing 5.83% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 127.65M, as it employees total of 64 workers.

Specialists analysis on Concert Pharmaceuticals Inc. (CNCE)

During the last month, 0 analysts gave the Concert Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 3.20, with a change in the price was noted +0.11. In a similar fashion, Concert Pharmaceuticals Inc. posted a movement of +3.29% for the period of last 100 days, recording 89,342 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CNCE is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Trends and Technical analysis: Concert Pharmaceuticals Inc. (CNCE)

Raw Stochastic average of Concert Pharmaceuticals Inc. in the period of last 50 days is set at 56.83%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 76.84%. In the last 20 days, the company’s Stochastic %K was 29.16% and its Stochastic %D was recorded 23.75%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 9.52%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -18.25%, alongside a downfall of -11.31% for the period of the last 12 months. The shares increased approximately by 5.83% in the 7-day charts and went down by 9.52% in the period of the last 30 days. Common stock shares were driven by 5.83% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts